MacroGenics Inc - Company Profile
Powered by 
All the data and insights you need on MacroGenics Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date MacroGenics Inc Strategy Report
- Understand MacroGenics Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
MacroGenics Inc (MacroGenics) is a biopharmaceutical company which focuses on the development and delivery of novel antibody-based therapeutics for the treatment of cancer, infectious diseases and autoimmune disorders. Its product pipeline includes candidates for the treatment of solid tumors, HIV, breast and gastroesophageal cancers, type 1 diabetes, DART product candidates for the treatment of acute myeloid leukemia and myelodysplastic syndrome; and b-cell malignancies. The company’s product candidates are based on proprietary technology platforms, namely, Cancer Stem Cell Platform, Dual-Affinity Re-Targeting (or DART) and TRIDENT Platform and FC Optimization Platform. It works in collaboration with various pharmaceutical and biotechnology companies to leverage its technology platforms and protein engineering capabilities for development. MacroGenics is headquartered in Rockville, Maryland, the US.
Headquarters
United States of America
Address
9704 Medical Center Drive, Rockville, Maryland, 20850
Website
www.macrogenics.com
Telephone
1 301 2515172
No of Employees
339
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
MGNX (NASD)
Revenue (2022)
$58.7M
-61.3%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
92.4%
(2022 vs 2021)
Market Cap*
$1.1B
Net Profit Margin (2022)
XYZ
80.4%
(2022 vs 2021)
* As of and is in US$
MacroGenics Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Platform Technologies: | Dart |
| Dual-Affinity Re-Targeting (DART) | Margenza |
| Fc Optimization | Trident |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Contracts/Agreements | In March, the company entered into an agreement to sell its royalty interest on future global net sales of TZIELD (teplizumab-mzwv) to a wholly-owned subsidiary of DRI Healthcare Trust. |
| 2022 | Regulatory Approval | In November, the company announced the U.S. Food and Drug Administration announced the approval of the Biologics License Application (BLA) for teplizumab. |
| 2022 | Contracts/Agreements | In October, the company and Gilead Sciences entered into an agreement to develop MGD024, an investigational, bispecific antibody. |
Competitor Comparison
| Key Parameters | MacroGenics Inc | F. Hoffmann-La Roche Ltd | Merck & Co Inc | Pfizer Inc | AbbVie Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | Switzerland | United States of America | United States of America | United States of America |
| City | Rockville | Basel | Kenilworth | New York | North Chicago |
| State/Province | Maryland | - | New Jersey | New York | Illinois |
| No. of Employees | 339 | 103,605 | 72,000 | 88,000 | 50,000 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| William Heiden | Chairman | Executive Board | 2022 | - |
| Scott Koenig, M.D., Ph.D. | President; Chief Executive Officer; Director | Executive Board | 2001 | - |
| James Karrels | Chief Financial Officer; Secretary; Senior Vice President | Senior Management | 2008 | - |
| Eric Risser | Chief Operating Officer | Senior Management | 2022 | - |
| Stephen Eck, M.D, Ph.D. | Chief Medical Officer; Senior Vice President - Clinical Development | Senior Management | 2020 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward